

International AMNOG Summit 2012

6th and 7th September in Berlin

Thursday, September 6th 2012

Time	Title	Speaker(s)
10:00-10:15	Introduction and Welcome	Dr Andreas Guhl, ValueMAxess Ltd
10:15-10:45	AMNOG – a fair assessment process?	Dr Norbert Gerbsch, Deputy Director General, German Pharmaceutical Industry Association, BPI
10:45-11:15	Making IQWiG assessments successful for companies	Dr Detlev Parow, Head of Department Patient Centered Care, Statutory Sick Fund DAK
11:15-11:45	What's next after IQWiG assessment?	Thomas Müller, Head of Pharmaceutical Department Joint Federal Committee GBA (requested) Dr Christian Rybak, Lawyer and AMNOG expert, Partner, Ehlers, Ehlers and Partner, Munich
11:45-12:15	The do's and don'ts in price negotiations	Wolfgang Kaesbach Former Head Pharmaceutical Department Statutory Health Insurance Fund GKV Spitzenverband
12:15-12:45	Last chance arbitration?	Professor Frank Ulrich Fricke, Member of the Joint Federal Arbitration Board
12:45-13:45	Lunch break	

Ask the experts workshops

13:45-14:45	Workshop 1: Get prepared for the AMNOG challenge. What companies can do at an early development stage to maximize positive assessment outcomes	Expert panel: Dr Norbert Gerbsch, Dr Christian Rybak, Dr Simone Breitkopf, Thomas Müller Hosted by: Dr Andreas Guhl
	Workshop 2: The critical AMNOG success factors. Experts report on how to overcome the AMNOG hurdle	Expert panel: Prof Frank Ulrich Fricke, Wolfgang Kaesbach, Dr Detlev Parow, Dr Tobias Gantner Hosted by: tbd
15:00-16:00	Repeat Workshop 1 and Workshop 2	
16:00	Closing remarks and coffee	

Friday, September 7th 2012

Time	Title	Speakers
AMNOG – How influential are IQWiG or GBA decisions on other markets? Get the points of view of international sponsors and industry		
9:00-9:15	Introduction and Welcome	Dr Andreas Guhl, ValueMAxess Ltd
9:15-11:00	Opportunities and pitfalls around AMNOG. Get insights from the experts: <ul style="list-style-type: none"> • G-BA scientific advice • Generating a benefit dossier and the financial burden • IQWiG assessment process • Slicing-IQWiG's new approach for drug assessments? • The GBA assessment process • Price negotiations with the GKV Spitzenverband 	Dr Tobias Gantner, Head Market Access Bayer Dr Simone Breitkopf, Medical Director Shire Dr Sabine Greulich VP Oncology / Virology Boehringer Ingelheim
11:00-11:30	Coffee break	
11:30-12:15	Ask the experts: Podium discussion with representatives of the pharmaceutical companies	
12:15-12:45	How important is health economics in the context of AMNOG? Gathering the right data to overcome the AMNOG hurdle	Professor York Zöllner, University for Applied Science Hamburg
12:45-13:45	Lunch break	

Market access across Europe
How influential are pricing and reimbursement decisions in Germany for other countries?

13:45-14:00	Market access challenges in UK	Representatives from NICE
14:00-14:15	Market access challenges in Scotland	Representatives from SMC
14:15-14:30	Market access challenges in the Netherlands	Ad Schuurman, Head of Business Contact Centre & International Affairs Dutch Health Care Insurance Board
14:30-14:45	Market access challenges in France	Prof Mondher Toumi, University Lyon
14:45-15:30	Podium discussion and Ask the experts session: What possible impact do IQWiG or GBA decisions have on other markets?	Representative NICE Representative SMC Ad Schuurman Prof Mondher Toumi
15:30	Closing remarks, coffee, networking	Dr Andreas Guhl, ValueMAxess